Participant flow15

How many started, completed or left each group, period by period.

1 to 15 of 15

Period	Milestone	Group	Participants
Overall Study	STARTED	Daridorexant 10 mg	142
Overall Study	STARTED	Daridorexant 25 mg	268
Overall Study	STARTED	Daridorexant 50 mg	137
Overall Study	STARTED	Placebo	128
Overall Study	STARTED	ExPlacebo/Daridorexant 25 mg	126
Overall Study	COMPLETED	Daridorexant 10 mg	99
Overall Study	COMPLETED	Daridorexant 25 mg	190
Overall Study	COMPLETED	Daridorexant 50 mg	93
Overall Study	COMPLETED	Placebo	78
Overall Study	COMPLETED	ExPlacebo/Daridorexant 25 mg	90
Overall Study	NOT COMPLETED	Daridorexant 10 mg	43
Overall Study	NOT COMPLETED	Daridorexant 25 mg	78
Overall Study	NOT COMPLETED	Daridorexant 50 mg	44
Overall Study	NOT COMPLETED	Placebo	50
Overall Study	NOT COMPLETED	ExPlacebo/Daridorexant 25 mg	36

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03679884/flow